MCID: ALL006
MIFTS: 60

Allergic Asthma

Categories: Immune diseases, Respiratory diseases

Aliases & Classifications for Allergic Asthma

MalaCards integrated aliases for Allergic Asthma:

Name: Allergic Asthma 12 24 14 69
Extrinsic Asthma with Acute Exacerbation 12
Extrinsic Asthma with Status Asthmaticus 12
Ige-Mediated Allergic Asthma 69
Extrinsic Asthma 24
Asthma Allergic 51
Atopic Asthma 12

Classifications:



Summaries for Allergic Asthma

Genetics Home Reference : 24 Asthma is a breathing disorder characterized by inflammation of the airways and recurrent episodes of breathing difficulty. These episodes, sometimes referred to as asthma attacks, are triggered by irritation of the inflamed airways. In allergic asthma, the attacks occur when substances known as allergens are inhaled, causing an allergic reaction. Allergens are harmless substances that the body's immune system mistakenly reacts to as though they are harmful. Common allergens include pollen, dust, animal dander, and mold. The immune response leads to the symptoms of asthma. Allergic asthma is the most common form of the disorder.

MalaCards based summary : Allergic Asthma, also known as extrinsic asthma with acute exacerbation, is related to aspergillosis and ige responsiveness, atopic, and has symptoms including coughing, wheezing and shortness of breath or has_symptom rapid breathing. An important gene associated with Allergic Asthma is IL13 (Interleukin 13), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Montelukast and Histamine have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An asthma that is characterized by symptoms that are triggered by an allergic reaction caused by inhaled allergens such as dust mite allergen, pet dander, pollen and mold. Allergic asthma is airway obstruction and inflammation that is partially reversible with medication. The disease has symptom coughing, has symptom wheezing, has symptom shortness of breath or has symptom rapid breathing, and has symptom chest tightness.

Related Diseases for Allergic Asthma

Diseases related to Allergic Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 31.8 CCL17 IFNG IL10 IL4 IL5
2 ige responsiveness, atopic 31.5 IFNG IGHE IL10 IL13 IL4 IL4R
3 helicobacter pylori infection 30.5 CCL5 IFNG IL10
4 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.5 IFNG IL10 IL17A
5 rhinitis 30.4 CCL11 CCL5 IGHE IL13 IL4 IL4R
6 intrinsic asthma 30.3 IL4 IL5 RNASE3
7 respiratory syncytial virus infectious disease 30.3 CCL5 IL13 IL5
8 eosinophilic gastroenteritis 30.3 CCL11 IL5 RNASE3
9 esophagitis 30.1 CCL11 IL13 IL5 TSLP
10 pneumonia 30.1 CCL11 CCL5 IL10 IL13 IL5
11 periodontitis 30.0 IFNG IL10 IL17A IL4
12 pulmonary eosinophilia 29.7 CCL11 CCL17 CCL5 IL13 IL4 IL5
13 rheumatoid arthritis 29.7 CCL5 IFNG IL10 IL17A IL4
14 vernal keratoconjunctivitis 29.7 CCL11 CCL5 IL13 IL4 IL5 RNASE3
15 gastroenteritis 29.7 CCL11 IFNG IL10 IL4 IL5 RNASE3
16 allergic rhinitis 29.6 CCL11 IFNG IGHE IL10 IL13 IL4
17 contact dermatitis 29.5 CCL17 IFNG IL10 IL17A IL4 IL5
18 esophagitis, eosinophilic, 1 29.5 CCL11 IL13 IL5 RNASE3 STAT6 TSLP
19 food allergy 29.2 IFNG IL10 IL13 IL4 IL5 MS4A2
20 keratoconjunctivitis 29.2 CCL11 CCL17 IFNG IL13 IL4 IL5
21 dermatitis 28.7 CCL11 CCL17 IFNG IGHE IL13 IL17A
22 allergic hypersensitivity disease 27.8 CCL11 CCL17 CCL5 IFNG IGHE IL10
23 asthma 27.0 ADAM33 CCL11 CCL17 CCL5 GATA3 IFNG
24 dermatitis, atopic 26.9 CCL11 CCL17 CCL5 GATA3 IFNG IGHE
25 mycoplasmal pneumonia 10.6 IFNG IL4
26 cytokine deficiency 10.6 IL13 IL5
27 tropical endomyocardial fibrosis 10.6 IL10 IL4
28 eosinophilic fasciitis 10.6 IFNG IL5
29 egg allergy 10.6 IGHE IL4 IL5
30 loeffler endocarditis 10.6 IL5 RNASE3
31 cough variant asthma 10.5 IL4 IL5 RNASE3
32 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL13 IL5
33 chronic tic disorder 10.5 IL13 IL4 IL5
34 pemphigoid gestationis 10.5 CCL11 IL5
35 blepharoconjunctivitis 10.5 CCL11 IL4 RNASE3
36 staphylococcal toxic shock syndrome 10.5 IFNG IGHE
37 hyperlucent lung 10.5 IFNG IL10 IL4
38 african tick-bite fever 10.5 CCL5 IFNG IL13
39 baylisascariasis 10.5 IFNG IL10 IL4
40 ascaridiasis 10.5 IL10 IL13
41 cow milk allergy 10.5 IL10 IL5 RNASE3
42 buruli ulcer 10.5 IFNG IL10 IL4
43 sinusitis 10.5 IL4R IL5 RNASE3
44 poliomyelitis 10.5 IFNG IL10 IL4
45 status asthmaticus 10.5 CCL5 IL5 RNASE3
46 multicentric castleman disease 10.5 IFNG IL10 IL5
47 coccidiosis 10.5 IFNG IL10 IL4
48 eales disease 10.5 IFNG IL10 IL4
49 ascaris lumbricoides infection 10.5 IFNG IL5 TSLP
50 esophageal disease 10.5 IL13 IL5 TSLP

Graphical network of the top 20 diseases related to Allergic Asthma:



Diseases related to Allergic Asthma

Symptoms & Phenotypes for Allergic Asthma

Symptoms:

12
  • coughing
  • wheezing
  • shortness of breath or has_symptom rapid breathing
  • chest tightness

MGI Mouse Phenotypes related to Allergic Asthma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 ITK MS4A2 STAT6 TSLP IL5 IL13
2 immune system MP:0005387 10.19 ITK MS4A2 NPSR1 STAT6 TSLP IL5
3 digestive/alimentary MP:0005381 10.06 IL5 TSLP IL13 GATA3 IL17A IFNG
4 endocrine/exocrine gland MP:0005379 10.02 ITK STAT6 IL4R IL13 GATA3 IL17A
5 integument MP:0010771 9.76 STAT6 TSLP IL10 IL4R IL13 GATA3
6 no phenotypic analysis MP:0003012 9.5 IL10 ADAM33 IL13 GATA3 IL17A IFNG
7 respiratory system MP:0005388 9.36 NPSR1 STAT6 TSLP IL5 IL13 CCL11

Drugs & Therapeutics for Allergic Asthma

Drugs for Allergic Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4,Phase 3,Phase 2 158966-92-8 5281040
2
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 51-45-6, 75614-87-8 774
3
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 242138-07-4
4
Norepinephrine Approved Phase 4 51-41-2 439260
5
Theophylline Approved Phase 4 58-55-9 2153
6
Nitric Oxide Approved Phase 4,Phase 3,Phase 2 10102-43-9 145068
7
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
8
Terbutaline Approved Phase 4 23031-25-6 5403
9
Zafirlukast Approved, Investigational Phase 4 107753-78-6 5717
10
Budesonide Approved Phase 4,Phase 2,Phase 3 51333-22-3 5281004 63006
11
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
12
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
13
Vancomycin Approved Phase 4 1404-90-6 14969 441141
14
Metronidazole Approved Phase 4 443-48-1 4173
15
Histamine Phosphate Phase 4,Phase 3,Phase 2 51-74-1 65513
16
Fluticasone Phase 4,Phase 3,Phase 2,Phase 1 80474-14-2, 90566-53-3 22833648 62924
17 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1
18 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
19 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1
20 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2,Phase 3,Phase 1
21 Adrenergic beta-Agonists Phase 4,Phase 2,Phase 3,Phase 1
22 Formoterol Fumarate Phase 4,Phase 2,Phase 3
23 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Allergic Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Phase 1
30 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
31 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
32 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Leukotriene Antagonists Phase 4,Phase 3,Phase 2
34 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
35 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
37 mometasone furoate Phase 4,Phase 3,Phase 2
38
Salmeterol xinafoate Phase 4 94749-08-3 56801
39 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
40 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2
41 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4
42 Adrenergic alpha-Agonists Phase 4
43 Cholinergic Antagonists Phase 4,Phase 2,Phase 3
44 Albuterol Phase 4,Phase 2,Phase 3,Phase 1
45 Tocolytic Agents Phase 4,Phase 2,Phase 3,Phase 1
46 Vasoconstrictor Agents Phase 4
47 Viscosupplements Phase 4
48 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
50 Immunoglobulin E Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 233)

# Name Status NCT ID Phase Drugs
1 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
2 mRNA Expression as a Biomarker of Omalizumab Response Unknown status NCT01584687 Phase 4
3 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Completed NCT00267202 Phase 4 Placebo;Omalizumab;Immunotherapy;Immunotherapy
4 Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma Completed NCT00870584 Phase 4 Omalizumab;Placebo
5 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists Completed NCT00670930 Phase 4 omalizumab at a dose of 0.016mg/kg/IU/mL;Placebo
6 Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids Completed NCT00691873 Phase 4 Placebo;Xolair
7 A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy Completed NCT00639691 Phase 4
8 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma Completed NCT00264849 Phase 4 Omalizumab
9 Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy Completed NCT00329381 Phase 4 Xolair;Xolair
10 Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma Completed NCT00567476 Phase 4 Omalizumab;Inhaled corticosteroids (ICS);Long-acting beta 2-adrenergic agonist (LABA);Short-acting beta 2-adrenergic agonist (SABA)
11 Prevention of Asthma and Allergy by Probiotic Lactobacillus GG Completed NCT00490425 Phase 4 Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)
12 Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen Completed NCT00518518 Phase 4 Staloral 300;placebo
13 The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients) Completed NCT00777764 Phase 4 Cohort I;Cohort 2
14 Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair Completed NCT00139152 Phase 4 Placebo;Xolair
15 Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils Completed NCT02023151 Phase 4 Omalizumab
16 A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy Completed NCT01125748 Phase 4 Omalizumab;Placebo;Asthma therapies
17 Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma Completed NCT00980707 Phase 4 Inhaled corticosteroid (fluticasone)
18 Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Completed NCT00492076 Phase 4
19 A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy Completed NCT00283504 Phase 4 ANTI-IGE THERAPY (XOLAIR)
20 Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma Completed NCT00546143 Phase 4 Omalizumab;Omalizumab;Omalizumab
21 A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair) Completed NCT01922037 Phase 4 Omalizumab
22 Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma Completed NCT00454051 Phase 4 Omalizumab;placebo
23 A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) Completed NCT00096954 Phase 4 omalizumab (Xolair);placebo
24 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
25 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed NCT00495612 Phase 4 Omalizumab;Placebo
26 Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma Completed NCT00490243 Phase 4 budesonide and montelukast;budesonide and formoterol;montelukast;budesonide;placebo
27 The Effect of Xolair (Omalizumab) on Allergy Blood Cells Completed NCT00657891 Phase 4 Omalizumab;Placebo
28 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations Completed NCT01430403 Phase 4 Inhaled Corticosteroid Boost Therapy (ICS)
29 C1-inhibitor in Allergic ASThma Patients Recruiting NCT03051698 Phase 4 C1-inhibitor;Antibiotics
30 Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280) Terminated NCT00070707 Phase 4 Nasonex
31 Correlation Between IgE Parameters and the Response to Omalizumab in Subjects With Severe Asthma Withdrawn NCT01002976 Phase 4
32 No Resistance After Long Term Treatment SERETIDE Withdrawn NCT00456313 Phase 4 FLIXOTIDE and SERETIDE
33 A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma Withdrawn NCT00242359 Phase 4 omalizumab
34 Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations Unknown status NCT01520051 Phase 3 Mepolizumab;Placebo
35 Omalizumab in Non-atopic Asthma Unknown status NCT01113437 Phase 2, Phase 3 Omalizumab;Placebo
36 Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma Completed NCT01976208 Phase 2, Phase 3 Omalizumab;placebo
37 Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy Completed NCT01202903 Phase 3 Omalizumab;Placebo
38 Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis Completed NCT00396409 Phase 3 Depigoid;Omalizumab;Placebo
39 Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma Completed NCT00829179 Phase 3 RhuMab-E25
40 Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children Completed NCT01328886 Phase 3 Omalizumab
41 Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma Completed NCT00482248 Phase 3 Omalizumab
42 A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma Completed NCT00109200 Phase 3 Xolair (omalizumab)
43 Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma Completed NCT00986323 Phase 3
44 Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) Completed NCT01155700 Phase 3 omalizumab
45 Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma Completed NCT00079937 Phase 3 Omalizumab;Placebo;Fluticasone
46 Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation. Completed NCT00500539 Phase 3 omalizumab
47 Fish Oil and Asthma in House Dust Mite Allergy Completed NCT00380926 Phase 2, Phase 3 polyunsatturated fatty acids (fish oil)
48 A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Completed NCT02596321 Phase 3 Mitizax;Placebo
49 Efficacy Of Bacterial Lysate In Asthmatic Children Completed NCT02541331 Phase 3
50 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED) Completed NCT00289874 Phase 3 montelukast sodium;Comparator: Placebo

Search NIH Clinical Center for Allergic Asthma

Genetic Tests for Allergic Asthma

Anatomical Context for Allergic Asthma

MalaCards organs/tissues related to Allergic Asthma:

38
Lung, T Cells, Testes, Skin, Neutrophil, B Cells, Smooth Muscle

Publications for Allergic Asthma

Articles related to Allergic Asthma:

(show top 50) (show all 825)
# Title Authors Year
1
Dexamethasone alleviates allergic asthma immature rat through Toll like receptor 4. ( 29364486 )
2018
2
Is eosinophilic esophagitis an equivalent of pollen allergic asthma? Analysis of biopsies and therapy guided by component resolved diagnosis. ( 29338961 )
2018
3
Expansion of a CD26<sup>low</sup>effector TH subset and reduction of circulating levels of sCD26 in stable allergic asthma in adults. ( 29297467 )
2018
4
Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma. ( 29318574 )
2018
5
Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab. ( 29300536 )
2018
6
Modeling Unobserved Heterogeneity in Susceptibility to Ambient Benzo[a]pyrene Concentration among Children with Allergic Asthma Using an Unsupervised Learning Algorithm. ( 29320438 )
2018
7
Advances and Evolving Concepts in Allergic Asthma. ( 29427987 )
2018
8
Activated Leukocyte Cell Adhesion Molecule Stimulates the T Cell Response in Allergic Asthma. ( 29394080 )
2018
9
Does adiposity mediate the relationship between socioeconomic position and non-allergic asthma in childhood? ( 29367283 )
2018
10
Biased Generation and In Situ Activation of Lung Tissue-Resident Memory CD4 T Cells in the Pathogenesis of Allergic Asthma. ( 29343554 )
2018
11
Allergic asthma is associated with increased risk of infections requiring antibiotics. ( 29413341 )
2018
12
Developmental endothelial locus-1 (Del-1) antagonizes Interleukin-17-mediated allergic asthma. ( 29437247 )
2018
13
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. ( 29422778 )
2018
14
Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma. ( 29302700 )
2018
15
IL-37 inhibits IL-4/IL-13-induced CCL11 production and lung eosinophilia in murine allergic asthma. ( 29319845 )
2018
16
Effect of polymorphisms on TGFB1 on allergic asthma and helminth infection in an African admixed population. ( 28284979 )
2017
17
Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. ( 28838980 )
2017
18
Inhibitory effects of l-theanine on airway inflammation in ovalbumin-induced allergic asthma. ( 27908701 )
2017
19
Response to omalizumab in patients with severe allergic asthma: A real-life study. ( 28947015 )
2017
20
Cost effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. ( 28532191 )
2017
21
Metabolic Plasticity in Dendritic Cell Responses: Implications in Allergic Asthma. ( 29387732 )
2017
22
The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. ( 28859150 )
2017
23
ERJ August Podcast: Fevipiprant in allergic asthma not controlled by low-dose inhaled corticosteroids. ( 28838974 )
2017
24
Propofol inhibits NF-I_B activation to ameliorate airway inflammation in ovalbumin (OVA)-induced allergic asthma mice. ( 28843179 )
2017
25
Omalizumab in non-allergic Asthma: A report of 13 cases. ( 28800272 )
2017
26
Murine Models of Allergic Asthma. ( 28063042 )
2017
27
The C5a/C5aR1 axis controls the development of experimental allergic asthma independent of LysM-expressing pulmonary immune cells. ( 28931049 )
2017
28
Bupleurum chinense extract ameliorates an OVA-induced murine allergic asthma through the reduction of the Th2 and Th17 cytokines production by inactivation of NFI_B pathway. ( 28531919 )
2017
29
Th9 and other IL-9-producing cells in allergic asthma. ( 27858144 )
2017
30
Systemic and mucosal pre-administration of recombinant Helicobacter pylori neutrophil-activating protein prevents ovalbumin-induced allergic asthma in mice. ( 28087613 )
2017
31
Trigonella foenum-graecum alleviates airway inflammation of allergic asthma in ovalbumin-induced mouse model. ( 27939889 )
2017
32
Role of PIM2 in allergic asthma. ( 28944837 )
2017
33
Differential regulation of PD-1 and its ligands in allergic asthma. ( 28865147 )
2017
34
MODERN APPROACHES TO FRACTIONAL EXHALED NITRIC OXIDE AS A USEFUL BIOMARKER FOR ALLERGIC ASTHMA PHENOTYPING AND MANAGEMENT. ( 29328030 )
2017
35
Deficiency of KLF4 compromises the lung function in an acute mouse model of allergic asthma. ( 28867182 )
2017
36
Sex-based differences in CD103<sup>+</sup>dendritic cells promote female-predominant Th2 cytokine production during allergic asthma. ( 29288569 )
2017
37
Ameliorative effects of Artemisia pallens in a murine model of ovalbumin-induced allergic asthma via modulation of biochemical perturbations. ( 28810518 )
2017
38
The Effect of Zataria multiflora on Th1/Th2 and Th17/T Regulatory in a Mouse Model of Allergic Asthma. ( 28824424 )
2017
39
Particulate allergens potentiate allergic asthma in mice through sustained IgE-mediated mast cell activation. ( 28920926 )
2017
40
Corrigendum: Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children. ( 28936430 )
2017
41
Involvements of p38 MAPK and oxidative stress in the ozone-induced enhancement of AHR and pulmonary inflammation in an allergic asthma model. ( 29284473 )
2017
42
LAT alleviates Th2/Treg imbalance in an OVA-induced allergic asthma mouse model through LAT-PLC-I^1 interaction. ( 28063403 )
2017
43
Chlamydia pneumoniae Induces Interferon Gamma Responses in Peripheral Blood Mononuclear Cells in Children with Allergic Asthma. ( 28480606 )
2017
44
TLR 7/8 Ligand, S28463, Suppresses Ascaris Suum Induced Allergic Asthma in Nonhuman Primates. ( 28850259 )
2017
45
Concomitant suppression of Th2 and Th17 cell responses in allergic asthma by targeting RORI^t. ( 28943467 )
2017
46
The Differences in Serum Quantitative Specific IgE Levels Induced by Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis Sensitization in Intermittent and Persistent Allergic Asthma. ( 29348379 )
2017
47
Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma. ( 28063043 )
2017
48
Maternal Exposure of BALB/c Mice to Indoor NO2 and Allergic Asthma Syndrome in Offspring at Adulthood with Evaluation of DNA Methylation Associated Th2 Polarization. ( 28935613 )
2017
49
Beneficial Effects of Prebiotic Saccharomyces cerevisiae Mannan on Allergic Asthma Mouse Models. ( 28835901 )
2017
50
Clinical evaluation of sublingual administration of dust mite drops in the treatment of allergic asthma and allergic rhinitis of children. ( 27831636 )
2016

Variations for Allergic Asthma

Expression for Allergic Asthma

Search GEO for disease gene expression data for Allergic Asthma.

Pathways for Allergic Asthma

Pathways related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 CCL11 CCL5 GATA3 IFNG IGHE IL10
2
Show member pathways
13.87 CCL11 CCL17 CCL5 IL10 IL13 IL16
3
Show member pathways
13.74 CCL11 CCL17 CCL5 IFNG IL10 IL13
4
Show member pathways
13.63 CCL11 CCL17 CCL5 IFNG IL10 IL13
5
Show member pathways
13.47 CCL11 CCL17 CCL5 IL10 IL13 IL16
6
Show member pathways
13.39 CCL11 CCL17 CCL5 IL10 IL13 IL16
7
Show member pathways
13.36 CCL11 CCL5 GATA3 IFNG IGHE IL10
8
Show member pathways
12.92 CCL11 IFNG IL10 IL13 IL17A IL4
9 12.87 IFNG IL13 IL4 IL4R IL5 STAT6
10
Show member pathways
12.74 IFNG IGHE IL10 IL4 IL4R ITK
11
Show member pathways
12.66 IGHE IL13 IL4 IL5 ITK MS4A2
12 12.65 CCL5 GATA3 IFNG IL10 IL17A IL4
13
Show member pathways
12.65 GATA3 IFNG IL10 IL13 IL17A IL4
14
Show member pathways
12.55 GATA3 IFNG IL10 IL17A IL4 IL5
15
Show member pathways
12.5 CCL11 GATA3 IGHE IL4 IL4R STAT6
16
Show member pathways
12.45 CCL11 CCL17 IFNG IL13 IL17A IL4
17
Show member pathways
12.39 IFNG IL10 IL13 IL4 IL4R IL5
18
Show member pathways
12.23 IFNG IL10 IL13 IL16 IL17A IL4
19 12.03 IFNG IL10 IL4 IL5
20
Show member pathways
11.98 GATA3 IFNG IL10 IL17A
21 11.93 GATA3 IFNG IL13 IL4 IL5
22
Show member pathways
11.92 IFNG IL17A IL4 IL4R
23 11.89 IFNG IL10 IL4R STAT6
24 11.85 IL4 IL4R IL5
25
Show member pathways
11.84 GATA3 IFNG IL4 IL5
26 11.83 GATA3 IFNG IL10 IL13 IL17A IL4
27 11.82 CCL5 IFNG IL17A
28 11.8 CCL11 CCL5 IL13 IL4 IL5
29 11.74 GATA3 IL10 IL5
30 11.67 IL10 IL4 IL5
31 11.67 CCL11 GATA3 IGHE IL10 IL13 IL17A
32 11.64 CCL5 IL10 IL13 IL4
33 11.56 CCL11 CCL17 IGHE IL10 IL4 IL4R
34 11.45 IFNG IL4 IL4R IL5
35 11.39 IFNG IL10 IL13 IL4 IL5
36 11.31 IFNG IL10 IL13 IL4 IL5
37 11.31 GATA3 IFNG IL13 IL17A IL4 IL5
38 11.25 CCL11 CCL17 CCL5 IL10 IL13 IL16
39 11.13 GATA3 IL4 IL4R STAT6
40 11.11 CCL11 CCL17 CCL5 IL10 IL13 IL16
41 10.98 CCL11 CCL17 GATA3 IFNG IL10 IL13
42 10.95 IL13 IL4 IL4R IL5

GO Terms for Allergic Asthma

Cellular components related to Allergic Asthma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 CCL11 CCL17 CCL5 IFNG IGHE IL10
2 external side of plasma membrane GO:0009897 9.46 IGHE IL13 IL17A MS4A2
3 extracellular space GO:0005615 9.44 CCL11 CCL17 CCL5 IFNG IL10 IL13

Biological processes related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.93 CCL17 CCL5 IL10 IL13 IL17A
2 cellular response to tumor necrosis factor GO:0071356 9.83 CCL11 CCL17 CCL5 GATA3
3 cellular response to interferon-gamma GO:0071346 9.82 CCL11 CCL17 CCL5
4 chemokine-mediated signaling pathway GO:0070098 9.81 CCL11 CCL17 CCL5
5 neutrophil chemotaxis GO:0030593 9.8 CCL11 CCL17 CCL5
6 response to virus GO:0009615 9.78 CCL11 CCL5 GATA3 IFNG
7 chemotaxis GO:0006935 9.77 CCL11 CCL17 CCL5 IL16 IL4
8 cellular response to interleukin-1 GO:0071347 9.76 CCL11 CCL17 CCL5 IL17A
9 inflammatory response GO:0006954 9.76 CCL11 CCL17 CCL5 IL10 IL13 IL17A
10 monocyte chemotaxis GO:0002548 9.75 CCL11 CCL17 CCL5
11 positive regulation of B cell proliferation GO:0030890 9.74 IL13 IL4 IL5
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 CCL5 IFNG IL13 TSLP
13 regulation of receptor activity GO:0010469 9.7 CCL11 CCL17 CCL5 IFNG IL10 IL13
14 leukocyte chemotaxis GO:0030595 9.65 IL10 IL16
15 positive regulation of mast cell degranulation GO:0043306 9.63 IL13 IL4R
16 eosinophil chemotaxis GO:0048245 9.63 CCL11 CCL5
17 positive regulation of immunoglobulin production GO:0002639 9.62 IL13 IL4R
18 positive regulation of interleukin-5 production GO:0032754 9.61 GATA3 TSLP
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL10 IL4
20 positive regulation of macrophage activation GO:0043032 9.61 IL10 IL13 IL4R
21 positive regulation of interleukin-5 secretion GO:2000664 9.6 GATA3 TSLP
22 type 2 immune response GO:0042092 9.59 IL10 IL4
23 positive regulation of interleukin-23 production GO:0032747 9.58 IFNG IL17A
24 interleukin-4-mediated signaling pathway GO:0035771 9.56 IL4R STAT6
25 negative regulation of endothelial cell apoptotic process GO:2000352 9.56 GATA3 IL10 IL13 IL4
26 regulation of isotype switching GO:0045191 9.55 IL10 IL4
27 positive regulation of isotype switching to IgE isotypes GO:0048295 9.51 IL4 STAT6
28 positive regulation of interleukin-13 production GO:0032736 9.5 GATA3 IL4 TSLP
29 negative regulation of complement-dependent cytotoxicity GO:1903660 9.49 IL13 IL4
30 immune response GO:0006955 9.44 CCL11 CCL17 CCL5 IFNG IGHE IL10

Molecular functions related to Allergic Asthma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 CCL11 CCL17 CCL5 IFNG IL10 IL13
2 chemokine activity GO:0008009 9.33 CCL11 CCL17 CCL5
3 CCR4 chemokine receptor binding GO:0031729 8.96 CCL17 CCL5

Sources for Allergic Asthma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....